TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01204840

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Growth Hormone
Description: Subjects in this trial will use a 3.33mg vial (1 vial =10 IU) by daily subcutaneous injection. This will start on day 1 of the menstrual cycle preceding the stimulation phase of an IVF cycle, and will continue until the day of the human chorionic gonadotropin (hCG) trigger (approximately 5-6 weeks)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Patch protocol
Description: Group A (n=10; control group) will receive patch protocol: 100ug estrogen patch (Estradot), Gonadotropin releasing hormone (GnRH) antagonist (Cetrotide; 0.25mg/d), gonadotropin stimulation 412 IU recombinant follicle stimulating hormone (r-FSH; Gonal F) and 150 IU of recombinant luteinizing hormone (r-LH; Luveris). With 3 or more follicles at mean diameter equal to or greater than 17mm, urinary human chorionic gonadotropin (u-hCG) 10,000 IU self-injected to complete final maturation of oocytes. Egg retrieval will occur 36 hours after hCG injection. Eggs fertilized by standard IVF or intra-cytoplasmic sperm injection (ICSI) depending on semen parameters. Embryos cultured to day 2 and the best 2-4 will be transferred back under ultrasound guidance. Surplus embryos will be frozen as per clinic protocol. Luteal support: Endometrin 100mg vaginally three times daily, starting on the day of egg retrieval and continuing until menses or positive serum beta-hCG, then stopped.
Study: NCT02013024

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: cryopreservation technique

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: cryopreservation technique
Study: NCT04492397

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Test Contact Lens
Description: Subjects will be randomized to wear test lenses.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Test Contact Lens
Description: Subjects will be randomized to wear test lenses.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Control Contact Lens
Description: Subjects will be randomized to wear control lenses.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Control Contact Lens
Description: Subjects will be randomized to wear control lenses.
Study: NCT00109850

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: cetuximab
Description: 400mg/m\^2 loading dose, intravenous (IV) over 120 min, day 1 of cycle 1 only. 250mg/m\^2 maintenance dose, IV over 60 min, Days 8 \& 15 of Cycle 1 and Days 1, 8, and 15 of subsequent cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: 30mg/m\^2, bolus intravenous (IV), on Days 1 \& 8 of each cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan hydrochloride
Description: 65mg/m\^2, intravenous (IV) over 30 min, on Days 1 \& 8 of each cycle.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: The total dose to the prescription point will be 5,040 cGy given in 28 fractions. The patient will be treated with one fraction per day with all fields treated per day. 180 cGy will be delivered to the isocenter. The dose variation in the planning target volume (PTV) will be +7% and -5% of the prescription point dose.
Study: NCT01150162

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rebamipide and Omeprazole
Description: open label, oral route, Rebamipide, 100mg tablet t.i.d and Omeprazole 20 mg tablet B.I.D. for 8 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Omeprazole
Description: open label,oral route, Omeprazole 20mg tablet, B. I.D.; alone, for 8 weeks
Study: NCT03721627

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ledipasvir/Sofosbuvir
Description: Direct acting anti HCV drugs
Study: NCT01185860

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: danoprevir
Description: oral doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: danoprevir
Description: oral doses

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: peginterferon alfa-2a [Pegasys]
Description: 180 mcg sc once weekly

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: peginterferon alfa-2a [Pegasys]
Description: 180 mcg sc once weekly

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: peginterferon alfa-2a [Pegasys]
Description: 180 mcg sc once weekly

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: oral doses

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ribavirin
Description: 1000-1200mg/day po

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ribavirin
Description: 1000-1200mg/day po

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ribavirin
Description: 1000-1200mg/day po

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ritonavir
Description: oral doses

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ritonavir
Description: oral doses
Study: NCT03747185

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Lumbopelvic stiffening technique
Description: Participants will stretch the hamstrings muscle in standing position with lumbopelvic stiffening technique. Fifteen percent of the body weight will be used to standardize stretching force. During stretching protocol, the participants will be instructed to face the hydraulic table with the hips square, maintain trunk straight up and look straight ahead. Researcher commands during adjusting the bed up, please tense the back rigid. After that, hydraulic bed will be lifted up until force reaches 15 percent of the body weight. Participant will perform 30 seconds/repetition for 4 repetitions with 15 seconds rest between repetitions.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lumbopelvic stiffening technique
Description: Participants will stretch the hamstrings muscle in standing position with lumbopelvic stiffening technique. Fifteen percent of the body weight will be used to standardize stretching force. During stretching protocol, the participants will be instructed to face the hydraulic table with the hips square, maintain trunk straight up and look straight ahead. Researcher commands during adjusting the bed up, please tense the back rigid. After that, hydraulic bed will be lifted up until force reaches 15 percent of the body weight. Participant will perform 30 seconds/repetition for 4 repetitions with 15 seconds rest between repetitions.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Lumbopelvic relaxing technique
Description: Participants will be instructed to face the hydraulic table with the hips square, maintain trunk straight up and look straight ahead. The researcher commands During adjusting the bed up, please relax the back. The hydraulic bed will be lifted up until force reaches 15 percent of the body weight. Participant will perform 30 seconds/repetition for 4 repetitions with 15 seconds rest between repetitions.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lumbopelvic relaxing technique
Description: Participants will be instructed to face the hydraulic table with the hips square, maintain trunk straight up and look straight ahead. The researcher commands During adjusting the bed up, please relax the back. The hydraulic bed will be lifted up until force reaches 15 percent of the body weight. Participant will perform 30 seconds/repetition for 4 repetitions with 15 seconds rest between repetitions.
Study: NCT01692886

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: 7-valent Pneumococcal Conjugate Vaccine
Description: suspension in prefilled syringe for intramuscular injection; 0.5 mL; one dose at 3-Month Visit, 4-Month Visit, 5-Month Visit, and 12-Month Visit, respectively

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 13-valent Pnumococcal Conjugate vaccine
Description: suspension in prefilled syringe for intramuscular injection; 0.5 mL; one dose at 3-Month Visit, 4-Month Visit, 5-Month Visit, and 12-Month Visit, respectively

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 13-valent Pnumococcal Conjugate vaccine
Description: suspension in prefilled syringe for intramuscular injection; 0.5 mL; one dose at 2-Month Visit, 4-Month Visit, 6-Month Visit, and 12-Month Visit, respectively

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 13-valent Pnumococcal Conjugate vaccine
Description: suspension in prefilled syringe for intramuscular injection; 0.5 mL; one dose at 3-Month Visit, 5-Month Visit, and 12-Month Visit, respectively
Study: NCT01785394

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5 grass allergen extract
Description: 30 patients will be subjected to sublingual immunotherapy with 5 grass allergen extract Staloral, starting with 1 spurt of 10 IR/ml increasing them daily stepwise to 10 spurts, switching then to 1 spurt of 300 IR/ml, increasing daily stepwise to 10 spurts, and then maintaining this dose from February till July. 30 patients will be on placebo.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 5 grass allergen extract
Description: 30 patients will be subjected to sublingual immunotherapy with 5 grass allergen extract Staloral, starting with 1 spurt of 10 IR/ml increasing them daily stepwise to 10 spurts, switching then to 1 spurt of 300 IR/ml, increasing daily stepwise to 10 spurts, and then maintaining this dose from February till July. 30 patients will be on placebo.
Study: NCT01212549

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Immunocryosurgery
Description: 2 weeks imiquimod, cryosurgery (open spray liquid nitrogen, 2 cycles, 15 secs each), 3 more weeks imiquimod

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cryoimmunotherapy
Description: Cryosurgery(open spray liquid nitrogen, 2 cycles, 15 secs each), followed by 5 weeks imiquimod
Study: NCT01042678

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MP0112
Description: Single intravitreal injection of MP0112 in the study eye

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MP0112
Description: Single intravitreal injection of MP0112 in the study eye

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MP0112
Description: Single intravitreal injection of MP0112 in the study eye

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MP0112
Description: Single intravitreal injection of MP0112 in the study eye

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MP0112
Description: Single intravitreal injection of MP0112 in the study eye

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MP0112
Description: Single intravitreal injection of MP0112 in the study eye
Study: NCT01611610

Intervention type: OTHER
Group type: OTHER
Intervention: Functional tests
Description: The ambulant patients will perform~* MFM (20 items)~* Hammersmith modified module - MHMFS~* Timed tests (time to rise from the floor,...)~* 6 minute walk test~* PedsQL - neuromuscular module

Intervention type: OTHER
Group type: OTHER
Intervention: Functional tests
Description: The non-ambulant patients will perform:~* MFM (20 items)~* Hammersmith modified module - MHMFS~* Upper Limb Functional Items~* Egen Klassifikation 2 questionnaire - EK2~* PedsQL questionnaire - neuromuscular module
Study: NCT01977209

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gossypol

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02407951

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBIT group
Description: Child group: 8 weekly group sessions lasting 90 mins, additional three monthly booster sessions.~During sessions, children create a tic hierarchy from most to least distressing, with more distressing tics addressed earlier in the treatment. Awareness training and competing response training is implemented and practiced. Competing response training is added, involving engagement in a voluntary behavior physically incompatible with the tic, contingent on the premonitory urge or other signs of impeding tic occurrence. Relaxation training addresses situations that sustained or worsened tics, training focuses on developing individual behavioral strategies to reduce the influence of these factor.~Parallel parent-group sessions simultaneously run during first 4 sessions of child-group. parents-group includes psycho-education and use of reward strategies.~Meetings executed by two trained clinicians.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Psycho-Educational group
Description: Child group: 8 weekly group sessions lasting 90 mins each, as well as additional three monthly booster sessions afterwards.~During the educational group sessions, each session will focus on educating the participants in regard to a specific subject: Tourette syndrome, Self-esteem, Anger, OCD (obssesive compulsive disorder), School and bullying, Anxiety, Attention, and a final session Quiz.~Parent group: Parent-group sessions will simultaneously run during the first 4 sessions of the child-group. The parents-group will include psycho-education and the use of reward strategies.~All group meetings will be executed and managed by two trained clinicians.
Study: NCT02840487

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VRC-ZKADNA085-00-VP
Description: VRC-ZKADNA085-00-VP is an investigational ZIKV DNA vaccine that is intended to prevent Zika virus infection.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VRC-ZKADNA085-00-VP
Description: VRC-ZKADNA085-00-VP is an investigational ZIKV DNA vaccine that is intended to prevent Zika virus infection.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VRC-ZKADNA085-00-VP
Description: VRC-ZKADNA085-00-VP is an investigational ZIKV DNA vaccine that is intended to prevent Zika virus infection.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VRC-ZKADNA085-00-VP
Description: VRC-ZKADNA085-00-VP is an investigational ZIKV DNA vaccine that is intended to prevent Zika virus infection.
Study: NCT04906655

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glycopyrronium 2.4 % Medicated Cloth
Description: The investigational product (glycopyrronium cloth, 2.4%) is a pre-moistened, medicated cloth towelette that comes in individually wrapped packets. Subjects will receive marketed Qbrexza, one box, containing 30 pouches.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glycopyrronium 2.4 % Medicated Cloth
Description: The investigational product (glycopyrronium cloth, 2.4%) is a pre-moistened, medicated cloth towelette that comes in individually wrapped packets. Subjects will receive marketed Qbrexza, one box, containing 30 pouches.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glycopyrronium 2.4 % Medicated Cloth
Description: The investigational product (glycopyrronium cloth, 2.4%) is a pre-moistened, medicated cloth towelette that comes in individually wrapped packets. Subjects will receive marketed Qbrexza, one box, containing 30 pouches.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glycopyrronium 2.4 % Medicated Cloth
Description: The investigational product (glycopyrronium cloth, 2.4%) is a pre-moistened, medicated cloth towelette that comes in individually wrapped packets. Subjects will receive marketed Qbrexza, one box, containing 30 pouches.
Study: NCT03689283

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dry Needling
Description: Individuals randomized to the Dry Needling Group will receive dry needling to latent trigger points of the gastrocnemius muscle

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Dry Needlling
Description: Individuals randomized to the Control group will receive sham needling to the gastrocnemius muscle
Study: NCT01840020

Intervention type: PROCEDURE
Intervention: Gastric bypass
Description: Surgical procedure in which the stomach is transected high on the body. The resulting small proximal gastric pouch is joined to any parts of the small intestine by an end-to-side surgical anastomosis.

Intervention type: PROCEDURE
Intervention: gastric sleeve
Description: Sleeve gastrectomy, a surgical procedure in which the stomach is reduced to about 25% of its original size, by surgical removal of a large portion of the stomach, following the major curve. The open edges are then attached together (often with surgical staples) to form a sleeve or tube with a banana shape.
Study: NCT01340235

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral erythromycin
Description: Severe Dowling Meara EBS patients from 6 months to 8 years old
Study: NCT03235544

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Parsaclisib
Description: Parsaclisib tablets administered orally with water and without regard to food.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Parsaclisib
Description: Parsaclisib tablets administered orally with water and without regard to food.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Parsaclisib
Description: Parsaclisib tablets administered orally with water and without regard to food.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Parsaclisib
Description: Parsaclisib tablets administered orally with water and without regard to food.
Study: NCT01833273

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PolyMVA
Description: Subjects will take 8 tsp/day of PolyMVA over a 26 week period while receiving standard of care from his/her neuro-oncologist. Subjects will begin taking the study compound after maximal surgical resection of the tumor and receiving an initial treatment of radiation therapy. Subjects will not take study compound on days when they receive chemotherapy.
Study: NCT00977327

Intervention type: DEVICE
Group type: OTHER
Intervention: Intraoperative MR (PoleStar N-20, Medtronics)
Description: intraoperative imaging for resection control of intraaxial brain lesions

Intervention type: DEVICE
Group type: OTHER
Intervention: Intraoperative Ultrasound (Sonowand, Mison)
Description: intraoperative imaging for resection control of intraaxial brain lesions
Study: NCT02544971

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Neurofeedback
Description: Neurofeedback is based on the learned change in a particular neural signal or a combination of neural signals when feedback and reward of these signals are repeatedly presented to the organism. Thus, individuals learn to modulate their neural activity through a closed NF loop.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Neurofeedback
Description: Neurofeedback is based on the learned change in a particular neural signal or a combination of neural signals when feedback and reward of these signals are repeatedly presented to the organism. Thus, individuals learn to modulate their neural activity through a closed NF loop.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Treatment as usual
Study: NCT03963245

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Meaningful Activities and Recovery
Description: MA\&R is a new rehabilitation program for people with psychiatric disabilities. MA\&R aims to enable participation in everyday activities that are meaningful to the individual.~MA\&R is based on occupational science, and the underlying premise that there is a connection between mental health, recovery and meaningful everyday activities. The goal of MA\&R is that participants through the course become better at connecting daily activities with values, interests, plans and goals. When this connection is strengthened, it supports the experience of meaningfulness in everyday life.~MA\&R is led by two mentors where one mentor is an occupational therapist (or similar) and the other has lived experiences of mental vulnerability and recovery.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Care and Treatment
Description: For community mental health centres: medicine, psychoeducation, relational support, peer-support, psychotherapy, social counselling, care manager~For psychiatric rehabilitation services in Copenhagen, Odense and Svendborg: drop in centres, relational support, skills training, peer-support

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard Care and Treatment
Description: For community mental health centres: medicine, psychoeducation, relational support, peer-support, psychotherapy, social counselling, care manager~For psychiatric rehabilitation services in Copenhagen, Odense and Svendborg: drop in centres, relational support, skills training, peer-support
Study: NCT03825367

Intervention type: DRUG
Group type: OTHER
Intervention: Nivolumab
Description: The dose of Nivolumab will be 3 mg/kg which is the adult recommended dose and is the recommended dose in children in the phase 2 portion of COG ADVL1412.~If 3 mg/kg is not tolerated in combination with 5-azacytidine, the dose will be stepped down to 1 mg/kg.

Intervention type: DRUG
Group type: OTHER
Intervention: 5-azacytidine
Description: 75mg/m2 subcutaneously will be given daily for 7 days on days 1 to 7.
Study: NCT04021758

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer to peer program intervention
Description: Peer to peer suicide prevention program aimed at reducing suicide in a military population.
Study: NCT01275976

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: C1-esterase inhibitor
Description: C1-esterase inhibitor 200 U/kg infusion over 30 minutes, just before the start of the femur or pelvic fixation operation.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline 0.9%
Description: Infusion, just before the start of the femur or pelvic fixation operation
Study: NCT00700245

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise-only (EXO-12 weeks of regular supervised exercise without diet restriction)
Description: The exercise intervention for subjects in the EXO consisted of supervised aerobic exercise three times per week with a duration of 60 -75 minutes pr. training session, with an estimated energy expenditure of 500-600 kcal per session. The subjects could choose between different modes of exercise; stationary bicycling, jogging on a treadmill or stair stepping.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Diet-only (DIO-8 weeks of very low energy diet (VLED 600 kcal/d) followed by 4 weeks weight maintenance diet
Description: Subjects in the DIO group were prescribed a liquid VLED(Nupo, Copenhagen) of respectively 600 and 800 kcal pr. day (proteins 41 g, carbohydrates 29 g, fat 5.6 g. pr 100 gram) for eight weeks followed by a weight maintenance diet for four weeks.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Diet+exercise (DEX-8 weeks VLED 800 kcal/d + a four weeks weight maintenance diet combined with regular supervised exercise throughout the 12 weeks).
Description: The exercise intervention for subjects in the DEX group consisted of supervised aerobic exercise three times per week with a duration of 60 -75 minutes pr. training session, with an estimated energy expenditure of 500-600 kcal per session